Updated:
Boryung Biopharma
Boryung Biopharma launched in 2014 as the single-family investment arm for the Kim family's Boryung Pharmaceutical, a publicly listed Korean drugmaker...
Boryung Biopharma
Boryung Biopharma launched in 2014 as the single-family investment arm for the Kim family's Boryung Pharmaceutical, a publicly listed Korean drugmaker founded in 1957. Rather than evolving into a conventional pharma-adjacent venture shop, the office adopted a thesis-driven posture anchored in low-Earth-orbit manufacturing. Chairman Kim Jung-kyun, a third-generation steward of the family enterprise, directs the platform from Seoul with operational offices in Wellesley, Massachusetts, and Orlando, Florida. The investment strategy centers on building a fully integrated space-to-pharma value chain. Core positions span orbital infrastructure, microgravity-enabled biology, and AI-driven drug discovery. The flagship relationship is with Axiom Space — Boryung led a $60 million strategic equity round in 2022 and committed a minimum of $100 million through a joint venture (per the firm, 2023). Additional named portfolio companies include Intuitive Machines, a lunar access provider, and Radian Aerospace, a single-stage-to-orbit vehicle developer. Boryung also backs synthetic biology platforms that design protein therapeutics optimized for space-based crystallization. The geographic footprint connects the Korean bio-cluster, Houston's aerospace corridor, and the Boston-Cambridge life-sciences ecosystem. September 2023 brought the launch of the Human Spaceflight & Care Accelerator, a $50 million vehicle targeting startups at the intersection of crewed space missions and biomedical research, operated jointly with Axiom Space and the Korean government (per the firm, September 2023). The total deployment across space-biotech efforts exceeds $250 million since 2020. While headcount remains undisclosed, Boryung operates through a lean internal deal team augmented by domain-specialist venture partners embedded in target hubs. The family retains operating control of Boryung Pharmaceutical through a legacy holding structure, with the investment office functioning as a separate balance-sheet allocator. What separates Boryung from other pharma-family offices is the vertical nature of its mandate: it is not a diversified LP but a strategic buyer of infrastructure that feeds an internal pipeline. The firm positions itself as a direct co-developer rather than a passive financial sponsor, taking board seats and shaping platform architectures at portfolio companies. This model exploits regulatory arbitrage — pharmaceutical manufacturing in microgravity faces fewer manufacturing facility constraints and intellectual property rules remain underdeveloped — giving Boryung a head start in a domain where peer family offices have yet to follow.
General information
Firm type
Single Family Office
Year founded
2014
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seoul
Corporate office
Seoul, South Korea
Additional offices
Wellesley, MA, United States · Orlando, FL, United States
Principals
Kim Jung-kyun
Chairman
Sector focus
Frequently asked questions
Who makes investment decisions at Boryung Biopharma?
Chairman Kim Jung-kyun is the lead investment decision-maker, operating the platform as a direct extension of the family's pharmaceutical balance sheet. The deal team includes venture partners based in US aerospace and biotech clusters rather than a large in-house generalist staff. Strategic decisions, including the Axiom Space partnership and the Human Spaceflight & Care Accelerator, bear his direct involvement.
How does Boryung source its space-biotech deal flow?
Boryung sources through its anchor partnership with Axiom Space, which provides visibility into orbital infrastructure and payload opportunities, and through direct scouting in Houston, Boston, and Seoul. The firm's joint-venture structure with the Korean government and its board-level relationships with portfolio companies like Intuitive Machines create a bilateral pipeline. Boryung also participates in NASA's Low Earth Orbit Economy working groups.
Does Boryung take direct equity positions, or does it operate through funds?
Boryung primarily takes direct equity positions and leads strategic rounds, as seen in the $60 million investment into Axiom Space in 2022. The firm also forms joint ventures and corporate-level accelerators rather than committing as a limited partner to third-party venture funds. The Human Spaceflight & Care Accelerator formalized this direct-engagement model with a dedicated $50 million allocation.
What is Boryung's relationship to Boryung Pharmaceutical?
Boryung Biopharma is the single-family investment vehicle for the Kim family, which founded and controls Boryung Pharmaceutical, a publicly traded Korean drugmaker established in 1957. The investment office operates separately from the pharma operating company, deploying family balance-sheet capital into space-biotech ventures. Chairman Kim Jung-kyun holds leadership roles across both entities.
Which sectors does Boryung explicitly avoid?
Boryung does not invest in pure-play terrestrial biotech startups that lack a space or microgravity application component. The firm also avoids generic pharmaceutical manufacturing, real estate, and broad-market public equities that fall outside the orbital biomanufacturing thesis. Its entire mandate is constrained to technologies that can advance or utilize low-Earth-orbit production and human spaceflight health sciences.
What total capital has Boryung deployed into space-biotech ventures?
Boryung has publicly disclosed over $250 million in space-biotech deployment since 2020, including the $60 million Axiom Space equity round in 2022, a minimum $100 million commitment through the Axiom joint venture, and a $50 million accelerator allocation in 2023. The firm has not disclosed a total AUM figure, and additional undisclosed direct investments are likely given the number of portfolio relationships.
Does Boryung co-invest alongside external GPs?
Boryung prefers to lead rounds or co-lead alongside strategic partners like Axiom Space and the Korean government rather than joining syndicates assembled by external general partners. The firm's posture is that of a value-chain strategic, not a passive co-investor. When other capital is involved, Boryung typically structures the vehicle or joint venture itself.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: